Background Cancer is the third-leading cause of death in the United Arab Emirates (UAE). There are few studies on cancer epidemiology in the UAE. Methods This retrospective study, from 2011 to 2013 until 2023, aimed to estimate the prevalence of a history of cancer and lifetime risk and identify its risk factors. Results Among 8635 cancer-free participants at the time of screening, 209 were diagnosed with new cancer (2.5%) over the follow-up period, 129 (1.9%) females compared to 80 (0.9%) males. The most common type of cancer was Breast cancer, with an incidence of 18% ( 37 cases ) out of the 209 total cases, all females. The second most common type was Thyroid Cancer, with 31 cases; 24 of them were females, and 7 were males. The third most common type was colon cancer, with 22 cases, 11 females and 11 males. Other types of cancer were found but had lower incidence, such as Adrenal, skin cancer, ovarian, bladder, and gastrointestinal GI cancers. The prevalence was comparable to the latest published report of the Abu Dhabi cancer registry in 2019. Among the whole cohort, Cox regression analysis showed only age and higher levels of HDL as risk factors for any cancer after screening when including possible risk factors that were assessed at baseline. The risk increases by 4.8% for each year older and 52% for each unit increase in HDL. The area Under the ROC Curve of the developed model for predicting any cancer type is 0.739 (0.707-0.771). Conclusion This study calls for focused research on different types of cancer to identify significant predictors to aid early diagnosis and management, as well as research on prevention and survival. This studys results provide critical input to the countrys decision-makers on cancer services and are informative internationally as the risk factors identified are prevalent worldwide and may be targeted with available interventions.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the AlAin Human Ethics Committee, approval number 13/58, and Ambulatory Healthcare Services IRB 19-2022. All methods were carried out under relevant guidelines and regulations. The authors confirm that the study was conducted in accordance with the Helsinki Declaration.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors